Changes in Beneficial Ownership · 4/A
Quoin Pharmaceuticals Ltd.
Changes in Beneficial Ownership
Structured filing — 4/A
tm2628307-1_4aseq1.xml
Amendment · This filing reports the amendment as submitted.
Filing details
- Report period
- 2026-08-27
- Original submission
- 2026-08-28
- Issuer
- Quoin Pharmaceuticals Ltd.
- Issuer CIK
- 0001671502
- Trading symbol
- QNRX
Reporting owner 1
- Name
- LANGER DENNIS
- Reporting owner CIK
- 0001274225
- Relationship
- Director
- Address
- C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN, VA, 20148
Non-derivative holdings
Table key
- D
- Direct
Footnotes
- F1
- Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.↩ 1
- F2
- On August 28, 2026, the reporting person filed a Form 4 (the "Original Form 4") which inadvertently overstated in column 5 the number of shares directly owned by the reporting person following the reported transaction. This inadvertent overstatement has been corrected in this amended filing.↩ 1
Signature 1
- Signed
- /s/ Dennis Langer
- Date
- 2026-10-26
Company context
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.